Gyre Therapeutics (GYRE) EBIAT (2016 - 2025)
Gyre Therapeutics (GYRE) has disclosed EBIAT for 16 consecutive years, with $5.9 million as the latest value for Q3 2025.
- On a quarterly basis, EBIAT rose 106.23% to $5.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.7 million, a 116.56% increase, with the full-year FY2024 number at $9.8 million, up 111.51% from a year prior.
- EBIAT was $5.9 million for Q3 2025 at Gyre Therapeutics, up from $1.6 million in the prior quarter.
- In the past five years, EBIAT ranged from a high of $51.6 million in Q2 2022 to a low of -$81.7 million in Q4 2023.
- A 5-year average of -$6.9 million and a median of -$540000.0 in 2024 define the central range for EBIAT.
- Peak YoY movement for EBIAT: crashed 453.61% in 2021, then skyrocketed 359.09% in 2022.
- Gyre Therapeutics' EBIAT stood at -$20.3 million in 2021, then tumbled by 37.21% to -$27.9 million in 2022, then crashed by 192.82% to -$81.7 million in 2023, then skyrocketed by 99.34% to -$540000.0 in 2024, then surged by 1190.74% to $5.9 million in 2025.
- Per Business Quant, the three most recent readings for GYRE's EBIAT are $5.9 million (Q3 2025), $1.6 million (Q2 2025), and $3.7 million (Q1 2025).